27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Reviewers at the FDA were leaning toward rejecting Sarepta Therapeutics Inc's (NASDAQ:SRPT) closely watched gene therapy for Duchenne muscular dystrophy.
- A top official had to intervene earlier this year, Stat News reported citing three people with direct knowledge of the agency deliberations.
- Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta's gene therapy should be rejected, the individuals said.
- Peter Marks, a top FDA official, stepped in and directed staff to schedule an advisory committee meeting on the therapy on May 12.
- The FDA seeks to optimize the development of gene therapies to help get accelerated approval of therapies by support using biomarkers as substitutes for other biological indicators in gene-therapy clinical trials.
- The advisory committee meeting will be hosted as a virtual meeting. SRP-9001 is Sarepta's investigational gene therapy for treating Duchenne muscular dystrophy.
- The FDA took a U-turn when it announced to hold an advisory committee meeting related to Sarepta's SRP-9001 (delandistrogene moxeparvovec) marketing application.
- In its Q4 earnings release, Sarepta said the mid-cycle meeting is complete, and FDA does not plan to hold an advisory committee for SRP-9001.
- Price Action: SRPT shares are down 5.75% at $129.76 on the last check Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!